US NEUROLOGY – SUPPLEMENT 1 – 2019
Spotlight debate—should we worry that pimavanserin might increase mortality amongst patients with Parkinson’s disease psychosis?
Introduction Of the estimated 10 million people worldwide who live with Parkinson’s disease (PD),1 over half will be expected to develop psychosis (hallucinations, illusions, delusions, or a false sense of presence).2,3 Pimavanserin (NUPLAZID®; ACADIA Pharmaceuticals Inc., San Diego, CA, USA) is an atypical antipsychotic developed for the treatment of hallucinations and delusions associated with PD […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!